Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Endometrial Cancer Treatment Market

Endometrial Cancer Treatment Market Trends

Report ID: GMI10810
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Endometrial Cancer Treatment Market Trends

Increasing prevalence of endometrial cancer is a significant driver of the endometrial cancer treatment industry.
For instance, according to GLOBOCAN estimates, in 2022, there were approximately 420,368 new cases of endometrial cancer (also known as uterine cancer) diagnosed worldwide. This figure positions endometrial cancer as the 15th most common cancer globally, with an age-standardized rate (ASR) of 8.4 per 100,000 women.
As the incidence of this cancer continues to rise, particularly among aging populations and individuals with risk factors such as obesity and hormonal imbalances, the demand for effective treatment options has grown substantially.
This rise in cases has led to an expanded need for diagnostic tools, innovative therapies, and personalized treatment approaches, fuelling market growth.
Additionally, advancements in early detection and a growing awareness of endometrial cancer have contributed to the market's expansion, as more patients are diagnosed at treatable stages, requiring immediate and ongoing medical interventions.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Market size for endometrial cancer treatment was valued at USD 28.9 billion in 2023 and will exhibit a 5.3% CAGR from 2024 to 2032, attributed to increasing incidence rates and rising awareness about early detection

The surgery segment in the endometrial cancer treatment industry will capture 5.2% CAGR through 2032, owing to its established role as a primary treatment method.

North America industry will reach USD 18.1 billion by 2032, driven by advanced healthcare infrastructure, widespread access to cutting-edge treatments, and high rate of early diagnosis.

Alpine Life Sciences Private Limited, AstraZeneca PLC, Eisai Co., Ltd., GSK plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Varian Medical Systems, Inc. (Siemens Healthineers AG), Sun Pharmaceutical Industries Limited, and Teva Pharmaceutical Industries Ltd., among others.